A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms ALIENOR
- 14 Mar 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
- 14 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2013 New source identified and integrated (European Clinical Trials Database record, EudraCT2012-002841-39).